Scott Beasley

πŸ’‰NEW: Phase 3 trial shows new non-vaccine way of preventing COVID provides significant reduction in infection & severe disease

βœ… 77% reduction of symptomatic COVID
βœ… No severe disease or death

πŸ’‰1st use of long-acting antibody (LAAB) combination

πŸ“Š 5,197 trial participants

πŸ’‰ The trial is called PROVENT and is of a new LAAB combination made by AstraZeneca- it is called AZD7442

🦠 It’s the first monoclonal antibody combination used as pre-exposure prophylaxis used against COVID

🌍 Trials took place in 87 sites in:

πŸ‡¬πŸ‡§ πŸ‡ΊπŸ‡Έ πŸ‡«πŸ‡· πŸ‡ͺπŸ‡Έ πŸ‡§πŸ‡ͺ

πŸ’‰ 5,197 people aged 18+ received either the the LAAB combination or a placebo

πŸ“‰ In those that got the drug infection was reduced by 77% and no one got severe disease or died

πŸ₯ More than 75% people had co-morbidities that can reduce immune response to vaccines

πŸ‘΄πŸ» 43% of people were aged over 60

πŸ₯ 75% had co-morbidities & other characteristics associated with an increased risk for severe COVID-19 should they become infected, including those with immunosuppressive disease or taking immunosuppressive medication etc

βœ… AZ is now preparing to go to regulators to seek emergency use authorisation for the treatment

πŸ’‰ It would be aimed at those for whom vaccines are less effective or not appropriate but would be given in a similar way

Myron Levin, Professor of Paediatrics & Medicine, University of Colorado School of Medicine & principal investigator:

β€œPROVENT data show one dose AZD7442, delivered in convenient intramuscular form, can quickly & effectively prevent symptomatic COVID-19….

…With these exciting results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to return to their normal lives.”

Fri Aug 20 06:45:10 +0000 2021